View Item 

Show simple item record

Parenteral Nutrition Administration Leads to Specific Alterations in the Expression of Adipocytokines and Peroxisome Proliferator‐Activated Receptors in a Rat Model
dc.contributor.authorTazuke, Yuko
dc.contributor.authorTeitelbaum, Daniel
dc.contributor.authorWasa, Masafumi
dc.contributor.authorFukuzawa, Masahiro
dc.contributor.authorIiboshi, Yasuhiko
dc.contributor.authorFujimoto, Jiro
dc.date.accessioned2018-02-05T16:42:27Z
dc.date.available2018-02-05T16:42:27Z
dc.date.issued2011-05
dc.identifier.citationTazuke, Yuko; Teitelbaum, Daniel; Wasa, Masafumi; Fukuzawa, Masahiro; Iiboshi, Yasuhiko; Fujimoto, Jiro (2011). "Parenteral Nutrition Administration Leads to Specific Alterations in the Expression of Adipocytokines and Peroxisome Proliferator‐Activated Receptors in a Rat Model." Journal of Parenteral and Enteral Nutrition 35(3): 329-336.
dc.identifier.issn0148-6071
dc.identifier.issn1941-2444
dc.identifier.urihttps://hdl.handle.net/2027.42/141876
dc.publisherWiley Periodicals, Inc.
dc.publisherSAGE Publications
dc.subject.otheradiponectin
dc.subject.otherparenteral nutrition
dc.subject.othernutrition
dc.subject.otherliver disease
dc.subject.otherresearch and diseases
dc.subject.otherlipids
dc.subject.othernutrition
dc.subject.otherchorestasis
dc.subject.othersteatosis
dc.subject.otherPPAR
dc.subject.othermetabolic syndrome
dc.titleParenteral Nutrition Administration Leads to Specific Alterations in the Expression of Adipocytokines and Peroxisome Proliferator‐Activated Receptors in a Rat Model
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPediatrics
dc.subject.hlbsecondlevelMedicine (General)
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumUniversity of Michigan, Ann Arbor, Michigan
dc.contributor.affiliationotherOsaka University Graduate School of Medicine, Osaka, Japan
dc.contributor.affiliationotherHyogo College of Medicine, Nishinomiya, Japan
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/141876/1/jpen0329-sup-0001.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/141876/2/jpen0329.pdf
dc.identifier.doi10.1177/0148607110381266
dc.identifier.sourceJournal of Parenteral and Enteral Nutrition
dc.identifier.citedreferenceWang H, Khaoustov VI, Krishnan B et al. Total parenteral nutrition induces liver steatosis and apoptosis in neonatal piglets. J Nutr. 2006; 136: 2547 – 2552.
dc.identifier.citedreferenceTazuke Y, Teitelbaum DH. Alteration of canalicular transporters in a mouse model of total parenteral nutrition. J Pediatr Gastroenterol Nutr. 2009; 48: 193 – 202.
dc.identifier.citedreferenceLee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator‐activated receptors. Endocrinology. 2003; 144: 2201 – 2207.
dc.identifier.citedreferenceSrivastava RA, Jahagirdar R, Azhar S, Sharma S, Bisgaier CL. Peroxisome proliferator‐activated receptor‐alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor‐deficient mice. Mol Cell Biochem. 2006; 285: 35 – 50.
dc.identifier.citedreferenceYamauchi T, Kadowaki T. The molecular mechanisms by which PPAR gamma/RXR inhibitors improve insulin resistance [in Japanese]. Nippon Rinsho. 2001; 59: 2245 – 2254.
dc.identifier.citedreferenceKok T, Bloks VW, Wolters H et al. Peroxisome proliferator‐activated receptor alpha (PPARalpha)‐mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. Biochem J. 2003; 369: 539 – 547.
dc.identifier.citedreferenceAuwerx J, Schoonjans K, Fruchart JC, Staels B. Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects. J Atheroscler Thromb. 1996; 3: 81 – 89.
dc.identifier.citedreferenceMatsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004; 24: 29 – 33.
dc.identifier.citedreferenceEsposito K, Giugliano D. The metabolic syndrome and inflammation: association or causation? Nutr Metab Cardiovasc Dis. 2004; 14: 228 – 232.
dc.identifier.citedreferenceMatsuzawa Y, Shimomura I, Kihara S, Funahashi T. Importance of adipocytokines in obesity‐related diseases. Horm Res. 2003; 60: 56 – 59.
dc.identifier.citedreferenceFukushima J, Kamada Y, Matsumoto H et al. Adiponectin prevents progression of steatohepatitis in mice by regulating oxidative stress and Kupffer cell phenotype polarization. Hepatol Res. 2009; 39: 724 – 738.
dc.identifier.citedreferenceTazuke Y, Drongowski RA, Btaiche I, Coran AG, Teitelbaum DH. Effects of lipid administration on liver apoptotic signals in a mouse model of total parenteral nutrition (TPN). Pediatr Surg Int. 2004; 20: 224 – 228.
dc.identifier.citedreferenceHasmall SC, West DA, Olsen K, Roberts RA. Role of hepatic nonparenchymal cells in the response of rat hepatocytes to the peroxisome proliferator nafenopin in vitro. Carcinogenesis. 2000; 21: 2159 – 2165.
dc.identifier.citedreferenceGoll V, Viollon‐Abadie C, Nicod L, Richert L. Peroxisome proliferators induce apoptosis and decrease DNA synthesis in hepatoma cell lines. Hum Exp Toxicol. 2000; 19: 193 – 202.
dc.identifier.citedreferenceTazuke Y, Wildhaber BE, Yang H, Washburn J, Teitelbaum DH. Total parenteral nutrition leads to alteration of hepatocyte cell cycle gene expression and proliferation in the mouse. Dig Dis Sci. 2007; 52: 920 – 930.
dc.identifier.citedreferenceTazuke Y, Wasa M, Shimizu Y, Wang HS, Okada A. Alanyl‐glutamine‐supplemented parenteral nutrition prevents intestinal ischemia‐reperfusion injury in rats. JPEN J Parenter Enteral Nutr. 2003; 27: 110 – 115.
dc.identifier.citedreferenceMorikawa N, Hagane K, Yokoyama J, Ishida H, Kitajima M. Effects of cyclic total parenteral nutrition on circadian rhythmicity of serum parameters, organ weight and histological findings of liver, kidney, and lung in rats. JSPS. 1995; 31: 577 – 588.
dc.identifier.citedreferenceKelly DA. Liver complications of pediatric parenteral nutrition—epidemiology. Nutrition. 1998; 14: 153 – 157.
dc.identifier.citedreferenceBriones ER, Iber FL. Liver and biliary tract changes and injury associated with total parenteral nutrition: pathogenesis and prevention. J Am Coll Nutr. 1995; 14: 219 – 228.
dc.identifier.citedreferenceHall RI, Grant JP, Ross LH, Coleman RA, Bozovic MG, Quarfordt SH. Pathogenesis of hepatic steatosis in the parenterally fed rat. J Clin Invest. 1984; 74: 1658 – 1668.
dc.identifier.citedreferenceZambrano E, El‐Hennawy M, Ehrenkranz RA, Zelterman D, Reyes‐Mugica M. Total parenteral nutrition induced liver pathology: an autopsy series of 24 newborn cases. Pediatr Dev Pathol. 2004; 7: 425 – 432.
dc.identifier.citedreferenceWanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990; 12: 1106 – 1110.
dc.identifier.citedreferenceTanaka Y, Yagi M. Pathogenesis of hepatobiliary dysfunction caused by total parenteral nutrition. Igaku No Ayumi (Jap). 2006; 18: 409 – 412.
dc.identifier.citedreferenceYoda‐Murakami M, Taniguchi M, Takahashi K et al. Change in expression of GBP28/adiponectin in carbon tetrachloride‐administrated mouse liver. Biochem Biophys Res Commun. 2001; 285: 372 – 377.
dc.identifier.citedreferenceTietge UJ, Boker KH, Manns MP, Bahr MJ. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab. 2004; 287: E82 – 89.
dc.identifier.citedreferenceTacke F, Wustefeld T, Horn R et al. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol. 2005; 42: 666 – 673.
dc.identifier.citedreferenceSohara N, Takagi H, Kakizaki S, Sato K, Mori M. Elevated plasma adiponectin concentrations in patients with liver cirrhosis correlate with plasma insulin levels. Liver Int. 2005; 25: 28 – 32.
dc.identifier.citedreferenceLiu CJ, Chen PJ, Lai MY et al. High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection. Hepatol Int. 2009; 3: 364 – 370.
dc.identifier.citedreferenceInukai K, Nakashima Y, Watanabe M et al. Regulation of adiponectin receptor gene expression in diabetic mice. Am J Physiol Endocrinol Metab. 2005; 288: E876 – 882.
dc.identifier.citedreferenceYamauchi T, Nio Y, Maki T et al. Targeted disruption of ADIPOR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007; 13: 332 – 339.
dc.identifier.citedreferenceHaluzik MM, Lacinova Z, Dolinkova M et al. Improvement of insulin sensitivity after peroxisome proliferator‐activated receptor‐alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels. Endocrinology. 2006; 147: 4517 – 4524.
dc.identifier.citedreferenceMaeda N, Takahashi M, Funahashi T et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose‐derived protein. Diabetes. 2001; 50: 2094 – 2099.
dc.identifier.citedreferenceHara K, Kubota N, Tobe K et al. The role of PPARgamma as a thrifty gene both in mice and humans. Br J Nutr. 2000; 84: S235 – S239.
dc.identifier.citedreferenceAuwerx J. PPARgamma, the ultimate thrifty gene. Diabetologia. 1999; 42: 1033 – 1049.
dc.identifier.citedreferenceCruccetti A, Pierro A, Uronen H, Klein N. Surgical infants on total parenteral nutrition have impaired cytokine responses to microbial challenge. J Pediatr Surg. 2003; 38: 138 – 142.
dc.identifier.citedreferenceDudrick SJ. Early developments and clinical applications of total parenteral nutrition. JPEN J Parenter Enteral Nutr. 2003; 27: 291 – 299.
dc.identifier.citedreferenceSandhu IS, Jarvis C, Everson GT. Total parenteral nutrition and cholestasis. Clin Liver Dis. 1999; 3: 489 – 508,viii.
dc.identifier.citedreferenceTeitelbaum DH. Parenteral nutrition‐associated cholestasis. Curr Opin Pediatr. 1997; 9: 270 – 275.
dc.identifier.citedreferenceBeath SV, Davies P, Papadopoulou A et al. Parenteral nutrition‐related cholestasis in postsurgical neonates: multivariate analysis of risk factors. J Pediatr Surg. 1996; 31: 604 – 606.
dc.identifier.citedreferenceGimmon Z. Total parenteral nutrition‐associated cholestasis. J Pediatr Gastroenterol Nutr. 1986; 5: 831.
dc.identifier.citedreferenceCapron JP, Gineston JL, Herve MA, Braillon A. Metronidazole in prevention of cholestasis associated with total parenteral nutrition. Lancet. 1983; 26: 446 – 447.
dc.identifier.citedreferenceKubota A, Yonekura T, Hoki M et al. Total parenteral nutrition‐associated intrahepatic cholestasis in infants: 25 years’ experience. J Pediatr Surg. 2000; 35: 1049 – 1051.
dc.identifier.citedreferenceSpiliotis JD, Kalfarentzos F. Total parenteral nutrition–associated liver dysfunction. Nutrition. 1994; 10: 255 – 260.
dc.identifier.citedreferenceMoss RL, Amii LA. New approaches to understanding the etiology and treatment of total parenteral nutrition–associated cholestasis. Semin Pediatr Surg. 1999; 8: 140 – 147.
dc.identifier.citedreferenceTazuke Y, Kiristioglu I, Heidelberger KP, Eisenbraun MD, Teitelbaum DH. Hepatic P‐glycoprotein changes with total parenteral nutrition administration. JPEN J Parenter Enteral Nutr. 2004; 28: 1 – 6.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jpen0329-sup-0001.pdf
Size:
184.1KB
Format:
PDF
View/Open
Name:
jpen0329.pdf
Size:
344.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.